AIM vs. CGTX, CVM, GRTS, DTIL, AVRO, ENTX, JATT, TSBX, ESLA, and CDTX
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include Cognition Therapeutics (CGTX), CEL-SCI (CVM), Gritstone bio (GRTS), Precision BioSciences (DTIL), AVROBIO (AVRO), Entera Bio (ENTX), JATT Acquisition (JATT), Turnstone Biologics (TSBX), Estrella Immunopharma (ESLA), and Cidara Therapeutics (CDTX). These companies are all part of the "biological products, except diagnostic" industry.
Cognition Therapeutics (NASDAQ:CGTX) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Cognition Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500.
Cognition Therapeutics has higher earnings, but lower revenue than AIM ImmunoTech. Cognition Therapeutics is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Cognition Therapeutics has a net margin of 0.00% compared to Cognition Therapeutics' net margin of -16,123.32%. AIM ImmunoTech's return on equity of -98.65% beat Cognition Therapeutics' return on equity.
AIM ImmunoTech received 45 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. Likewise, 82.35% of users gave AIM ImmunoTech an outperform vote while only 61.11% of users gave Cognition Therapeutics an outperform vote.
In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 2 articles in the media. AIM ImmunoTech's average media sentiment score of 0.94 beat Cognition Therapeutics' score of 0.74 indicating that Cognition Therapeutics is being referred to more favorably in the media.
Cognition Therapeutics currently has a consensus price target of $9.17, indicating a potential upside of 286.78%. Given AIM ImmunoTech's higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than AIM ImmunoTech.
Summary
Cognition Therapeutics beats AIM ImmunoTech on 10 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
